How have Unity Biotechnology Inc. (UBX)’s performance and profitability changed over the time?

Unity Biotechnology Inc. [UBX] stock is trading at $0.43, up up 1.62%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The UBX shares have lost -10.12% over the last week, with a monthly amount drifted -23.92%, and not seem to be holding up well over a long-time horizon.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


On 19, September 2022, UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration. In a post published today on Yahoo Finance, Enrollment of 51 patients exceeds target by ~10% due to high interest in the study.

From an analyst’s perspective:

Unity Biotechnology Inc. [NASDAQ: UBX] stock has seen the most recent analyst activity on January 04, 2022, when ROTH Capital upgraded its rating to a Buy. Previously, Mizuho upgraded its rating to Buy on November 10, 2021, and elevated its price target to $7. On June 28, 2021, upgrade upgraded it’s rating to Buy but maintained its price target of $6 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $12 on June 07, 2021. Citigroup downgraded its rating to a Sell and raised its price target to $6 on February 16, 2021. Morgan Stanley downgraded its rating to Equal-Weight for this stock on August 18, 2020, but kept the price target unchanged to $5. In a note dated August 18, 2020, Mizuho downgraded an Neutral rating on this stock and revised its target price from $33 to $4.

Unity Biotechnology Inc. [UBX] stock has fluctuated between $0.42 and $3.64 over the past year. Currently, Wall Street analysts expect the stock to reach $7.83 within the next 12 months. Unity Biotechnology Inc. [NASDAQ: UBX] shares were valued at $0.43 at the most recent close of the market. An investor can expect a potential return of 1720.93% based on the average price forecast.

Analyzing the UBX fundamentals

Gross Margin for this corporation currently stands at +39.80% with Operating Margin at -1184.47%, Pretax Margin comes in at -1269.34%, and Net Margin reading is -1269.34%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.4181 points at the first support level, and at 0.4038 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.4395, and for the 2nd resistance point, it is at 0.4466.

Unity Biotechnology Inc. [UBX] reported earnings per share of -$0.28 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.26/share, meaning a difference of $-0.02 and a surprise factor of -7.70%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.18 per share as compared to estimates of -$0.38 per share, a difference of $0.2 representing a surprise of 52.60%.

Ratios To Look Out For

For context, Unity Biotechnology Inc.’s Current Ratio is 4.10. Further, the Quick Ratio stands at 5.45, while the Cash Ratio is 5.33. Considering the valuation of this stock, the price to sales ratio is 17.03, the price to book ratio is 1.54.

Transactions by insiders

Insider trading, which has resulted in 0 insider purchases of 0 shares and 3 insider sales of 26,993 shares in the past three months, is now the topic of our analysis. Recent insider trading involved Ghosh Anirvan, Chief Executive Officer, that happened on Sep 14 when 13706.0 shares were sold. Chief Medical Officer, Dananberg Jamie completed a deal on Sep 14 to sell 10923.0 shares. Meanwhile, Chief Executive Officer Ghosh Anirvan sold 10446.0 shares on Aug 01.